Résumé
Objective To study the effects of containing bismuth sequential therapy on interleukin-10 (IL-10) and interleukin-17 (IL-17) in patients with peptic ulcer.Methods 162 patients with peptic ulcer were randomly divided into two groups,the observation group(n =81 cases) and the control group (n =81 cases).The patients in the observation group were treated through containing bismuth sequential therapy,while the patients in the control group were treated through traditional triple therapy.IL-10 and IL-17 were detected before and after treatment.Results The total effective rates were 97.5% in the observation group and 87.7% in the control group,which of the two groups had significantly difference (x2 =3.96,P ＜ 0.05).Hp eradication rate of the observation group was 96.3 %,and which of the control group was 80.2%,and there was significant difference between the two groups (x2 =4.17,P ＜ 0.05).IL-10 and IL-17 in both groups were significantly decreased after treatment.There was a significant difference between two groups after treatment (t =3.7244,9.3422,all P ＜ 0.05).Conclusion Bismuth-containing sequential therapy can significantly reduce IL-10 and IL-17 in the serum of patients with peptic ulcer.
Résumé
Objective: To select suitable conditions for prokaryotic expression and purification of rhIL-17. Methods: rhIL-17 was expressed in E. coli host under heat induction. After compared among the expression amounts in different media under different heat induction time, the most suitable conditions was selected. The target protein was present in the form of inclusion body. The precipitate of inclusion was obtained and purified after 6M guanidine solublization or 2% SDS solublization. Results: Either protocol could yield rhIL-17 with high purity and stable activity. The SDS solublization mehthod gives rise to much more higher productivity than the guanidine solublization method. Conclusion: rhIL-17 were expression in E. coli system and purified to homogenicity by SDS solublization methods with high productivity.